Acepodia Announces Expansion of Board of Directors and Scientific Advisory Board
January 06, 2022 08:00 ET
|
Acepodia USA
David V. Smith to join Board of Directors Elizabeth Smith and Richard Lopez, M.D., to join Scientific Advisory Board ALAMEDA, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Acepodia, a clinical-stage...
Acepodia Raises $109 Million Series C Financing to Advance Development of First-in-Class Antibody Cell Effector Therapies
December 02, 2021 08:00 ET
|
Acepodia USA
ALAMEDA, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Acepodia, a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) platform...
Acepodia Strengthens Board of Directors and Scientific Advisory Board with Key Appointments
November 03, 2021 08:00 ET
|
Acepodia USA
ALAMEDA, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Acepodia, a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) platform...
Acepodia Presents Positive Interim Phase 1 Feasibility Data for Antibody Cell Effector Therapy, ACE1702, in Advanced HER2-Positive Tumors
September 16, 2021 02:30 ET
|
Acepodia USA
Interim results from ongoing Phase 1 dose-escalation study demonstrate safety and tolerability of repeat dosing with ACE1702, a novel, off-the-shelf natural killer cell therapy Initial results show...
Acepodia to Present Data from Preclinical and Phase 1 Studies of ACE1702 at the European Society for Medical Oncology (ESMO) 2021 Virtual Congress
September 13, 2021 08:00 ET
|
Acepodia USA
ALAMEDA, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Acepodia, a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) platform...
Acepodia Publishes Preclinical Data on Novel Off-the-Shelf Natural Killer Cell Therapy, ACE1702, for HER2-Expressing Solid Tumors Using Antibody-Cell Conjugation Technology in the Journal Cancers
June 07, 2021 08:00 ET
|
Acepodia USA
ACE1702 showed superior in vitro and in vivo potency against HER2-expressing cancers Data support continued development of ACE1702 as a potent, safe, off-the-shelf natural killer (NK) cell therapy...
Acepodia Presents Data on its Allogeneic Natural Killer-Like Gamma-Delta T Cell Therapy, ACE1831, in Development for Hematological Cancers
May 19, 2021 08:00 ET
|
Acepodia USA
Preclinical data demonstrate potential of off-the-shelf, NK-like gamma-delta T cells in developing cell therapies for the treatment of cancers ACE1831, an allogeneic cell therapy candidate...
Acepodia Appoints Thorsten Graef, M.D., Ph.D., as Chief Medical Officer and Michael Brock as Chief Strategy Officer
May 11, 2021 08:00 ET
|
Acepodia USA
SAN MATEO, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- Acepodia, a biotechnology company developing next generation solid tumor and hematologic cancer cell therapies, today announced the appointments...
Acepodia CEO and Co-founder, Sonny Hsiao, Ph.D., to Present at Allogeneic Cell Therapies Summit 2021
May 10, 2021 08:00 ET
|
Acepodia Biotech Inc.
SAN MATEO, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- Acepodia, a biotechnology company developing next generation solid tumor and hematologic cancer cell therapies, today announced that Sonny Hsiao,...